[Translation] Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multicenter trial evaluating oral BI 1810631 as first-line therapy versus standard therapy in patients with unresectable, locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations
在经组织学证实诊断为携带HER2 TKD突变的不可切除、局部晚期或转移性非鳞状NSCLC且未接受过任何针对这一阶段疾病全身治疗的患者中,根据无进展生存期(PFS)的风险比证实zongertinib(BI 1810631)优于SoC(帕博利珠单抗+铂类药物-培美曲塞化疗)。
[Translation] In patients with histologically confirmed unresectable, locally advanced, or metastatic nonsquamous NSCLC harboring a HER2 TKD mutation who had not received any prior systemic therapy for this stage of disease, zongertinib (BI 1810631) was superior to SoC (pembrolizumab plus platinum-pemetrexed chemotherapy) based on the hazard ratio for progression-free survival (PFS).